Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Aug 2023: Trial started, NCT05997615
  2. 18 Aug 2023: Trial registered, NCT05997615

The trials

NCT05997615: Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

State
Under way
Phase
Phase 1
People
347 planned
Started
10 Aug 2023
Primary completion
30 Sep 2027
Arms
Part 3b: VIR-5500 in Combination with Docetaxel ± ARSI for Dose Escalation, Part 4b: VIR-5500 in Combination with Docetaxel ± ARSI for Dose Expansion
Results
None posted
  1. 10 Aug 2023: Trial started
  2. 18 Aug 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.